Literature DB >> 12763686

Innate and adaptive mucosal immunity in protection against HIV infection.

Thomas Lehner1.   

Abstract

Control of the HIV pandemic requires an effective vaccine. The difficulties in developing a preventive vaccine are generally believed to be due to the rapid rate of mutation of HIV that escapes cytotoxic lymphocytes (CTL) and the problems in induction of neutralising antibodies to wild strains of HIV. These difficulties should re-orientate vaccine strategy into four somewhat neglected areas of immunisation. Innate immunity, with its rapid protective response to infection that is independent of memory and relies on an optimal mucosal adjuvant. Targeting the genital and rectal mucosa, with the associated lymph nodes, as an immune response has to be elicited directly on encountering HIV during sexual intercourse. Stimulating a broadly based adaptive immune response that enhances the memory CD4(+) and CD8(+) T cells and B cells, induces maturation of dendritic cells and results in Th1 polarised immunity. Taking advantage of "experiments of nature", by utilising host antigens, as manifested by protection against HIV infection in homozygous Delta32 CCR5 individuals and in allo-immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763686     DOI: 10.1016/s0264-410x(03)00204-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity.

Authors:  Theresa L Chang; Jesus Vargas; Armando DelPortillo; Mary E Klotman
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 2.  Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

Authors:  E G Rhee; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 3.  Novel vaccine development strategies for inducing mucosal immunity.

Authors:  Yoshiko Fujkuyama; Daisuke Tokuhara; Kosuke Kataoka; Rebekah S Gilbert; Jerry R McGhee; Yoshikazu Yuki; Hiroshi Kiyono; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2012-03       Impact factor: 5.217

4.  Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.

Authors:  C Barassi; E Soprana; C Pastori; R Longhi; E Buratti; F Lillo; C Marenzi; A Lazzarin; A G Siccardi; L Lopalco
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts.

Authors:  Carla Donadoni; Cinzia Bisighini; Lorenza Scotti; Lorenzo Diomede; Marie Ngyen; Janin Nouhin; Lucia DeSantis; Antonella Zambon; Davide Ferrari; Giulia Gallotta; Giovanni Corrao; Gianfranco Pancino; Lucia Lopalco
Journal:  PLoS One       Date:  2010-03-29       Impact factor: 3.240

6.  Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners.

Authors:  Yi Liu; Amanda Woodward; Haiying Zhu; Thomas Andrus; John McNevin; Jean Lee; James I Mullins; Lawrence Corey; M Juliana McElrath; Tuofu Zhu
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

7.  CCR5: From Natural Resistance to a New Anti-HIV Strategy.

Authors:  Lucia Lopalco
Journal:  Viruses       Date:  2010-02-05       Impact factor: 5.818

8.  R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes.

Authors:  Hua Nian; Wen-Qing Geng; Hua-Lu Cui; Ming-jia Bao; Zi-ning Zhang; Min Zhang; Ying Pan; Qing-Hai Hu; Hong Shang
Journal:  BMC Infect Dis       Date:  2012-01-14       Impact factor: 3.090

Review 9.  HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies.

Authors:  Nyasha Chin'ombe; Vurayai Ruhanya
Journal:  Pan Afr Med J       Date:  2015-04-20

10.  Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4+ and CD8+ T-Cell Responses.

Authors:  Ulrike Sauermann; Antonia Radaelli; Nicole Stolte-Leeb; Katharina Raue; Massimiliano Bissa; Carlo Zanotto; Michael Krawczak; Matthias Tenbusch; Klaus Überla; Brandon F Keele; Carlo De Giuli Morghen; Sieghart Sopper; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2017-11-14       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.